Rifaximin
(2019) Study No. 413
Approved small_molecule active
Quick answer
Rifaximin for IBS - Irritable Bowel Syndrome is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- IBS - Irritable Bowel Syndrome
- Phase
- Approved
- Modality
- small_molecule
- Status
- active